Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRTC 
PureTech Health PLC (PRTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: PRTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $53.25
1 Year Target Price $53.25
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.68% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 446.87M USD | Price to earnings Ratio 8.86 | 1Y Target Price 53.25 |
Price to earnings Ratio 8.86 | 1Y Target Price 53.25 | ||
Volume (30-day avg) 2 | Beta 0.9 | 52 Weeks Range 13.30 - 25.00 | Updated Date 07/17/2025 |
52 Weeks Range 13.30 - 25.00 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1108.33% | Operating Margin (TTM) -1530.2% |
Management Effectiveness
Return on Assets (TTM) -13.1% | Return on Equity (TTM) 6.42% |
Valuation
Trailing PE 8.86 | Forward PE - | Enterprise Value 86188005 | Price to Sales(TTM) 92.56 |
Enterprise Value 86188005 | Price to Sales(TTM) 92.56 | ||
Enterprise Value to Revenue 19.97 | Enterprise Value to EBITDA 2.31 | Shares Outstanding 24025400 | Shares Floating 164801187 |
Shares Outstanding 24025400 | Shares Floating 164801187 | ||
Percent Insiders - | Percent Institutions 1.64 |
Upturn AI SWOT
PureTech Health PLC
Company Overview
History and Background
PureTech Health PLC is a biotherapeutics company that focuses on developing medicines to treat serious diseases. Founded in 2002, it has evolved into a company building a pipeline of therapeutic candidates across a variety of modalities.
Core Business Areas
- Therapeutics Development: Discovery and development of novel therapies, including small molecules, antibodies, and cell therapies. Focus areas include immunology, oncology, and metabolic diseases.
- Venture Creation: Creation of new biotech companies based on its internal research and external opportunities.
- Clinical Trials: Conducting Clinical Trials on new therapeutics.
Leadership and Structure
PureTech Health PLC is led by a board of directors and an executive management team. The company operates with a decentralized structure, empowering its subsidiaries and venture creations.
Top Products and Market Share
Key Offerings
- Karuna Therapeutics (acquired by Bristol Myers Squibb): Developed KarXT for schizophrenia, a novel M1/M4-preferring muscarinic agonist. Bristol Myers Squibb acquired Karuna in late 2023 for $14 billion; competes with existing antipsychotics from companies like Johnson & Johnson and AstraZeneca.
- Vor Biopharma: Developing engineered hematopoietic stem cell (eHSC) therapies to create treatment options for patients with cancer. Competitors in the cell therapy field include Gilead and Novartis. Revenue not directly attributable to PureTech.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. Trends include personalized medicine, gene therapy, and immunotherapy.
Positioning
PureTech Health PLC positions itself as an innovator and venture creator in the biotherapeutics space, seeking to identify and develop promising therapies with significant unmet medical needs.
Total Addressable Market (TAM)
The global biopharmaceutical market is worth over $1.5 Trillion. PureTech aims to develop therapies for significant unmet needs in diseases such as cancer.
Upturn SWOT Analysis
Strengths
- Strong track record of creating successful biotech ventures
- Diversified portfolio of therapeutic candidates
- Experienced management team
- Innovative approach to drug discovery
Weaknesses
- High reliance on success of individual portfolio companies
- Long development timelines and high R&D costs
- Dependence on regulatory approvals
- Complex corporate structure
Opportunities
- Growing demand for innovative therapies
- Advancements in drug discovery technologies
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Economic downturn impacting investment in biotech
Competitors and Market Share
Key Competitors
- LLY
- BMY
- MRK
- VRTX
- GILD
Competitive Landscape
PureTech Health PLC operates in a highly competitive landscape. The company's advantage lies in its venture creation model and its ability to identify and develop promising therapies. Disadvantages include dependence on regulatory approvals and long development timelines.
Major Acquisitions
Karuna Therapeutics (acquired by Bristol Myers Squibb)
- Year: 2023
- Acquisition Price (USD millions): 14000
- Strategic Rationale: Bristol Myers Squibb acquired Karuna to expand its neuroscience portfolio and gain access to KarXT for schizophrenia.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the success of ventures like Karuna Therapeutics. This will need to be quantified using stock price and financial data.
Future Projections: Future growth is dependent on the progress of current therapeutic candidates and the creation of new ventures. Analyst estimates would provide quantifiable growth projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for its portfolio companies and seeking strategic partnerships.
Summary
PureTech Health PLC is a biotechnology company operating under a venture creation model. It identifies and develops promising therapeutics, creating new companies focused on specific areas. Karuna's acquisition by Bristol Myers Squibb demonstrates the potential of this model, but the company faces risks associated with lengthy drug development timelines, regulatory hurdles, and dependence on the success of individual portfolio companies. Continued success requires effective management of these challenges and successful advancement of its current pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- PureTech Health PLC Investor Relations
- SEC Filings
- Analyst Reports
- Industry News Sources
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PureTech Health PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-11-16 | CEO & Executive Director Dr. Bharatt M. Chowrira J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.puretechhealth.com |
Full time employees 56 | Website https://www.puretechhealth.com | ||
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.